FAGRON

Fagron NV delivers personalized pharmaceutical care globally through three segments: Essentials, Brands, and Compounding Services. The company innovates products and formulations for compounding. Its products include various excipients, phytocomplexes, and pharmaceuticals for skin, hair, and immune system treatment. Fagron also offers education and training programs through the Fagron Academy.

Overview

Sector

Pharmaceutical

Target Price

14.3 EUR

Current Price

22.6 EUR

Potential

-37%

Strengths

EV/EBIT (16.95) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -36.37%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company has high debt. Net Debt to EBITDA Ratio (2.57) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (10.59%) is significantly lower than the sector mean (14.71%).

Key Financial Data

Indicator	Value
PER	20.4
EV/EBITDA	12.6
Price/Free Cash Flow'	23.8
ROIC	10.6%
Net Debt/EBITDA	2.6